Science | 24 May 2023 | News
IIT-Kanpur explores use of G-protein coupled receptors for drug discovery
A group of researchers led by Prof. Arun K Shukla in the Department of Biological Sciences and Bioengineering ...Read more
Opinion | 22 May 2023 | Views
"Players like us can ease entry of Indian pharma industry into drug discovery space"
When did you establish KnowDis/Molecule AI, and what was the key objective? We established KnowDis in 2018. I...Read more
MedTech | 20 May 2023 | News
The Union Minister for Chemicals and Fertilizers Dr Mansukh Mandaviya will inaugurate the 8th edition of ...Read more
Start-ups | 25 May 2023 | News
TechInvention & Reagent IVD Resources to develop comprehensive range of diagnostics
TechInvention Lifecare, a Mumbai-based biotech startup, has entered into a strategic collaboration with Reagen...Read more
Supplier | 19 May 2023 | News
Revvity announces new license agreement for next-generation base editing technology
US-based Revvity, Inc. (previously affiliated with PerkinElmer, Inc.) has announced a new license ag...Read more
People | 24 May 2023 | News
Health tech startup MedRabbits names Rana Bhattacharyya as GM- International Business
Pune-based healthcare tech startup, MedRabbits has announced the appointment of Rana Bhattacharyya as their ne...Read more
Academics | 24 May 2023 | News
Moksh releases comprehensive guide for Indian students on MBBS education in Russia
Mumbai-based Moksh Overseas Educon Limited, a leading study abroad consulting company in India,...Read more
Text blogs | 27 May 2023 | Views
Biotech Dreams Within Reach: 5 Insider Tips and Tricks for Success
The field of biotechnology holds immense potential for innovation and discovery. As the industry continues to ...Read more
Could 7.5% R&D Spends Make India PHARMA INNOVATION HUB?
Areport by India Brand Equity Foundation (IBEF) stated that India’s domestic pharmaceutical market was estimated at $42 billion in 2021, which is likely to reach $ 65 billion by 2024 and may further expand to reach nearly $120-130 billion by 2030. The country’s vast pool of scientific talent, strong system of higher education, low operating costs, conducive regulatory environment and supportive government policies have made it an attractive destination for drug development, clinical trials, and commercial manufacturing. A growing population, significant R&D investments, a modernised manufacturing base and the prevalence of chronic diseases have fuelled the growth of the pharma sector. And the backbone of the success can be largely attributed to robust R&D measures in recent years. Post COVID-19, pharma players have increased their R&D investment.
For Feedback, please email us at: communications@mmactiv.com